Adocia
115 avenue Lacassagne
Lyon
69003
France
Tel: +33-(0)4-72-610-610
Fax: +33-(0)4-72-363-967
Website: http://www.adocia.com/
About Adocia
Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia’s insulin formulation portfolio, featuring four clinical-stage products and one preclinical product, is among the largest and most differentiated in the industry.YEAR FOUNDED:
December 2005
LEADERSHIP:
Founders: Gérard Soula, Olivier Soula, and Rémi Soula
CEO: Gérard Soula
CFO: Valérie Danaguezian
JOBS:
Please click here for Adocia job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
117 articles about Adocia
-
Adocia Announces Appointment Of Dr. Stanislav Glezer As Chief Medical Officer
7/27/2017
-
Adocia Presents First Half 2017 Financial Results
7/19/2017
-
Adocia Initiates A Phase Ib Clinical Study On The Dose-Proportionality Of Biochaperone Combo In People With Type 2 Diabetes
6/8/2017
-
Adocia Announces Six Data Presentations At American Diabetes Association 77th Scientific Sessions
6/7/2017
-
Adocia Announces Positive Topline Results From A Meal-Test Clinical Study Of Biochaperone Combo In People With Type 2 Diabetes
6/7/2017
-
Adocia Initiates A Study Comparing Ultra-Rapid Insulin BioChaperone Lispro U100 With Fiasp And Novolog Administered With An Insulin Pump
6/2/2017
-
Adocia Launches First-in-Man Clinical Study Of BioChaperone Glucagon
6/1/2017
-
Adocia Announces First Quarter 2017 Financial Results
4/18/2017
-
Adocia Announced Its Financial Results For 2016 And Its Perspectives For 2017
3/7/2017
-
Adocia Announces Its Revenue And Cash Position For 2016
2/14/2017
-
Adocia To Present At The Leerink Partners 6th Annual Global Healthcare Conference
2/13/2017
-
Eli Lilly Bails Out of Ultra-Rapid Insulin Deal With Adocia
1/27/2017
-
Adocia To Hold Conference Call Providing An Update On Its Programs
1/25/2017
-
Adocia And Eli Lilly Announce Successful Completion Of An Insulin Pump Study With Biochaperone Lispro In People With Type 1 Diabetes
12/19/2016
-
Adocia Receives The 1st Prize For "Profitable Growth" And The 3rd "Technology Fast 50" Prize As Part Of The 2016 Deloitte In Extenso Technology Fast 50 Grand Rhône Alpes
11/8/2016
-
Adocia Announces Positive Topline Results From A Phase 1b Clinical Trial Measuring The Post-Meal Effect Of Rapid-Acting Human Insulin, Hinsbet U100
10/31/2016
-
Adocia Announces Third Quarter 2016 Financial Results
10/13/2016
-
Adocia Received The EY Global Company Award For The Auvergne Rhône-Alpes Region
9/22/2016
-
Adocia Announces New BioChaperone Program Combining A Basal Insulin And GLP-1s
9/14/2016
-
Adocia To Present Clinical Data Validating BioChaperone Technology At The 2016 EASD Annual Meeting
9/8/2016